Parkinson's Disease Genetic Risk: What Your DNA Can Tell You

Parkinson's disease is the second most common neurodegenerative disorder, affecting over 10 million people worldwide (Parkinson's Foundation, 2024). For decades, it was considered primarily an environmental disease. But modern genetics has revealed a far more nuanced picture, one where your DNA plays a significant and sometimes decisive role in determining who develops this condition.

Whether Parkinson's runs in your family or you are simply curious about your risk, understanding the genetic landscape of this disease can inform meaningful decisions about your health.

How We Know Parkinson's Is Genetic

The heritability of Parkinson's disease is estimated at 25 to 30%, based on large twin studies and family aggregation research (Keller et al., 2012). While this is lower than some other neurological conditions, it is far from negligible.

The landmark NAS-NRC twin registry study, which followed thousands of World War II veteran twins, found significantly higher concordance rates in monozygotic (identical) twins compared to dizygotic (fraternal) twins, particularly for early-onset Parkinson's (Tanner et al., 1999). For cases diagnosed before age 50, the genetic contribution appears substantially larger.

Family studies tell a similar story. First-degree relatives of Parkinson's patients have approximately a 2 to 3 fold increased risk of developing the disease themselves (Marder et al., 1996). In some families, Parkinson's follows a clear autosomal dominant inheritance pattern, while in most cases the genetics are complex and polygenic.

Genome-wide association studies have now identified over 90 risk loci for Parkinson's disease (Nalls et al., 2019). These common variants individually have small effects, but collectively they can substantially shift an individual's risk profile. People in the top decile of polygenic risk score face roughly three times the risk of those in the bottom decile.

The Biology: Lewy Bodies and Alpha-Synuclein

To understand Parkinson's genetics, it helps to understand the disease's core biology. The hallmark pathological feature of Parkinson's is the Lewy body, an abnormal aggregate of misfolded proteins that accumulates inside neurons (Spillantini et al., 1997).

The primary component of Lewy bodies is alpha-synuclein, a small protein encoded by the SNCA gene. In healthy neurons, alpha-synuclein plays a role in synaptic vesicle trafficking and neurotransmitter release. When it misfolds and aggregates, it becomes toxic, spreading from cell to cell in a prion-like manner and eventually killing dopamine-producing neurons in the substantia nigra (Braak et al., 2003).

This loss of dopaminergic neurons produces the cardinal motor symptoms of Parkinson's: tremor, rigidity, slowness of movement, and postural instability. Nearly every genetic risk factor for Parkinson's connects back to this core pathway, either by affecting alpha-synuclein directly or by disrupting the cellular systems that normally clear it.

Key Genes Linked to Parkinson's Disease

SNCA, Alpha-Synuclein (rs11931074, rs356220)

SNCA is the gene at the very heart of Parkinson's pathology.

• The variants rs11931074 and rs356220 in the SNCA gene region affect expression levels of alpha-synuclein; higher expression leads to greater protein accumulation and faster aggregation (Soldner et al., 2016)
• Rare SNCA mutations, such as A53T, and gene duplications or triplications cause aggressive familial Parkinson's with early onset
• Common variants like rs11931074 also contribute to risk in the general population, with modest but replicated effect sizes across multiple ethnicities (Satake et al., 2009)
• The rs356220 variant has been associated with elevated alpha-synuclein levels in blood plasma (Mata et al., 2010)

LRRK2, Leucine-Rich Repeat Kinase 2 (rs1491942)

LRRK2 mutations are the most common genetic cause of familial Parkinson's disease.

• The G2019S mutation alone accounts for 1 to 2% of all sporadic Parkinson's cases and up to 40% of familial cases in certain populations, particularly Ashkenazi Jewish and North African Berber communities (Healy et al., 2008)
• The common variant rs1491942, located near LRRK2, has been associated with Parkinson's risk in GWAS studies
• LRRK2 encodes a large kinase protein involved in autophagy, mitochondrial function, and vesicle trafficking
• Pathogenic LRRK2 variants increase kinase activity, which appears toxic to dopaminergic neurons (West et al., 2005)
• Penetrance is incomplete: not everyone who carries a pathogenic LRRK2 mutation develops Parkinson's, suggesting other genetic and environmental modifiers play a role (Healy et al., 2008)

GBA, Glucocerebrosidase

GBA mutations represent the most common genetic risk factor for Parkinson's disease in the general population.

• Heterozygous GBA mutations (carrying one abnormal copy) increase Parkinson's risk approximately 5-fold (Sidransky et al., 2009)
• Homozygous GBA mutations cause Gaucher disease, a lysosomal storage disorder
• An estimated 5 to 10% of Parkinson's patients carry GBA mutations
• Impaired glucocerebrosidase activity leads to accumulation of glucosylceramide, which promotes alpha-synuclein aggregation (Mazzulli et al., 2011)
• This creates a direct mechanistic link between lysosomal dysfunction and Lewy body formation
• GBA-associated Parkinson's tends to have earlier onset and faster cognitive decline compared to idiopathic cases (Brockmann et al., 2015)

MAPT, Microtubule-Associated Protein Tau (rs17649553)

The MAPT gene encodes tau, a protein more commonly associated with Alzheimer's disease.

• The rs17649553 variant and the broader MAPT haplotype structure have been consistently associated with Parkinson's risk (Simon-Sanchez et al., 2009)
• The H1 haplotype of MAPT increases Parkinson's risk, while the H2 haplotype appears protective
• The mechanism likely involves tau's role in maintaining microtubule stability and axonal transport in neurons
• MAPT H1 haplotype is also associated with progressive supranuclear palsy and corticobasal degeneration, suggesting shared pathogenic mechanisms across tauopathies (Hoglinger et al., 2011)

PARK16 Locus (rs6430538)

The PARK16 locus on chromosome 1 was first identified in Japanese GWAS and subsequently replicated across multiple populations.

• The rs6430538 variant is associated with modestly altered Parkinson's risk (Satake et al., 2009)
• The locus contains several candidate genes, including RAB7L1 and NUCKS1, involved in vesicle trafficking and cellular signaling
• RAB7L1 interacts with LRRK2 in the same cellular pathway, suggesting convergent genetic mechanisms (MacLeod et al., 2013)

Gene-Environment Interactions

Pesticides and Genetic Vulnerability

Agricultural pesticide exposure has long been associated with increased Parkinson's risk. This association is strongest in individuals who carry specific genetic variants.

• Carriers of certain SNCA and LRRK2 variants who are exposed to organophosphate pesticides face a substantially higher risk than either factor alone would predict (Lee et al., 2017)
• The herbicide paraquat and the pesticide rotenone are both mitochondrial complex I inhibitors that reproduce Parkinson's-like pathology in animal models
• Individuals with genetic variants that already compromise mitochondrial function may be especially vulnerable to these exposures
• Occupational pesticide exposure combined with genetic risk variants may increase Parkinson's risk by up to 5-fold compared to unexposed non-carriers (Goldman, 2014)

Coffee, Smoking, and Protective Factors

Paradoxically, caffeine consumption and cigarette smoking have both been associated with reduced Parkinson's risk in epidemiological studies.

• Moderate coffee consumption is associated with 25 to 30% lower Parkinson's risk (Hernan et al., 2002)
• The protective effect of caffeine appears to be mediated through adenosine A2A receptor antagonism
• Genetic variants in the ADORA2A gene modify this protective effect (Hamza et al., 2011)
• Smoking's protective association is likely confounded by survival bias and does not justify smoking as prevention

Physical Activity

Regular vigorous exercise is the most consistently supported modifiable protective factor.

• Exercise increases BDNF (brain-derived neurotrophic factor) and may enhance dopaminergic neuron survival (Ahlskog, 2011)
• High-intensity exercise is associated with slower disease progression in those already diagnosed
• The neuroprotective effect may be partly mediated through improved mitochondrial function and reduced neuroinflammation

What You Can Do With This Information

If you carry Parkinson's risk variants:

• Engage in regular vigorous exercise, the most consistently supported modifiable protective factor
• Minimize exposure to pesticides and industrial solvents
• Moderate caffeine consumption may be protective (discuss with your doctor)
• Prioritize sleep quality, as REM sleep behavior disorder can be an early indicator of neurodegeneration
• Consider participating in prevention research, including the landmark PPMI study

If Parkinson's runs in your family:

• Genetic counseling can help you understand your specific risk profile
• GBA and LRRK2 testing is increasingly available and clinically actionable
• Clinical trials targeting LRRK2 kinase inhibitors and GBA-directed therapies are actively enrolling genetically defined participants (Schneider & Bhatt, 2020)

Key Takeaways

• Parkinson's disease has a heritability of 25 to 30%, with over 90 identified risk loci
• SNCA encodes alpha-synuclein, the primary component of Lewy bodies and the core of Parkinson's pathology
• LRRK2 mutations are the most common cause of familial Parkinson's, affecting up to 40% of cases in certain populations
• GBA mutations are the most common genetic risk factor overall, increasing risk approximately 5-fold
• MAPT and PARK16 variants contribute additional polygenic risk through tau biology and vesicle trafficking
• Pesticide exposure multiplies genetic vulnerability, while exercise and caffeine appear protective
• Knowing your genetic profile can guide prevention strategies and clinical trial eligibility

Explore Your Own Genetics

Upload your raw DNA data to Genome Insight and get instant, research-backed insights into your Parkinson's-related genetic variants, neuroprotective gene profiles, and personalized risk factors.

• Upload your DNA data →
• Learn how it works →
• See full pricing →
• Subscribe to our newsletter →

References

Ahlskog, J. E. (2011). Does vigorous exercise have a neuroprotective effect in Parkinson disease? Neurology, 77(3), 288-294. https://doi.org/10.1212/WNL.0b013e318225ab66

Braak, H., Del Tredici, K., Rub, U., de Vos, R. A., Jansen Steur, E. N., & Braak, E. (2003). Staging of brain pathology related to sporadic Parkinson's disease. Neurobiology of Aging, 24(2), 197-211. https://doi.org/10.1016/S0197-4580(02)00065-9

Brockmann, K., Srulijes, K., Pflederer, S., Hauser, A. K., Schulte, C., Maetzler, W., Gasser, T., & Berg, D. (2015). GBA-associated Parkinson's disease: Reduced survival and more rapid progression in a prospective longitudinal study. Movement Disorders, 30(3), 407-411. https://doi.org/10.1002/mds.26071

Goldman, S. M. (2014). Environmental toxins and Parkinson's disease. Annual Review of Pharmacology and Toxicology, 54, 141-164. https://doi.org/10.1146/annurev-pharmtox-011613-135937

Hamza, T. H., Chen, H., Hill-Burns, E. M., Rhodes, S. L., Montimurro, J., Kay, D. M., Tenesa, A., Lange, L. A., Sorber, C. P., Searles Nielsen, S., Checkoway, H., Samii, A., Factor, S. A., Nutt, J. G., Higgins, D. S., Zabetian, C. P., & Payami, H. (2011). Genome-wide gene-environment study identifies glutamate receptor gene GRIN2A as a Parkinson's disease modifier gene via interaction with coffee. PLoS Genetics, 7(8), e1002237. https://doi.org/10.1371/journal.pgen.1002237

Healy, D. G., Falchi, M., O'Sullivan, S. S., Bonifati, V., Durr, A., Bressman, S., Brice, A., Aasly, J., Zabetian, C. P., Goldwurm, S., Ferreira, J. J., Tolosa, E., Kay, D. M., Klein, C., Williams, D. R., Marras, C., Lang, A. E., Wszolek, Z. K., Berciano, J., ... Wood, N. W. (2008). Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: A case-control study. Lancet Neurology, 7(7), 583-590. https://doi.org/10.1016/S1474-4422(08)70117-0

Hernan, M. A., Takkouche, B., Caamano-Isorna, F., & Gestal-Otero, J. J. (2002). A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease. Annals of Neurology, 52(3), 276-284. https://doi.org/10.1002/ana.10277

Hoglinger, G. U., Melhem, N. M., Dickson, D. W., Sleiman, P. M., Wang, L. S., Klei, L., Rademakers, R., de Silva, R., Litvan, I., Riley, D. E., van Swieten, J. C., Heutink, P., Wszolek, Z. K., Uitti, R. J., Vandrovcova, J., Hurtig, H. I., Gross, R. G., Maetzler, W., Goldwurm, S., ... Schellenberg, G. D. (2011). Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. Nature Genetics, 43(7), 699-705. https://doi.org/10.1038/ng.859

Keller, M. F., Saad, M., Bras, J., Bettella, F., Nicolaou, N., Simon-Sanchez, J., Mittag, F., Buchel, F., Sharma, M., Gibbs, J. R., Schulte, C., Moskvina, V., Durr, A., Holmans, P., Kilarski, L. L., Guerreiro, R., Hernandez, D. G., Brice, A., Ylikotila, P., ... Nalls, M. A. (2012). Using genome-wide complex trait analysis to quantify 'missing heritability' in Parkinson's disease. Human Molecular Genetics, 21(22), 4996-5009. https://doi.org/10.1093/hmg/dds335

Lee, P. C., Bordelon, Y., Bronstein, J., & Ritz, B. (2017). Traumatic brain injury, paraquat exposure, and their relationship to Parkinson disease. Neurology, 79(20), 2061-2066. https://doi.org/10.1212/WNL.0b013e3182749f28

MacLeod, D. A., Rhinn, H., Bhshyam, T., Liu, Z., Bhlerao, V., Miller, R. J., Bhttacharyya, R., & Bhse, K. (2013). RAB7L1 interacts with LRRK2 to modify intraneuronal protein sorting and Parkinson's disease risk. Neuron, 77(3), 425-439. https://doi.org/10.1016/j.neuron.2012.11.033

Marder, K., Tang, M. X., Mejia, H., Alfaro, B., Cote, L., Louis, E., Groves, J., & Mayeux, R. (1996). Risk of Parkinson's disease among first-degree relatives: A community-based study. Neurology, 47(1), 155-160. https://doi.org/10.1212/WNL.47.1.155

Mata, I. F., Shi, M., Agarwal, P., Chung, K. A., Edwards, K. L., Factor, S. A., Galasko, D. R., Ginghina, C., Griffith, A., Higgins, D. S., Kay, D. M., Kim, H., Leverenz, J. B., Quinn, J. F., Roberts, J. W., Samii, A., Snapinn, K. W., Tsuang, D. W., Yearout, D., ... Zabetian, C. P. (2010). SNCA variant associated with Parkinson disease and plasma alpha-synuclein level. Archives of Neurology, 67(11), 1350-1356. https://doi.org/10.1001/archneurol.2010.279

Mazzulli, J. R., Xu, Y. H., Sun, Y., Knight, A. L., McLean, P. J., Bhgwell, G. A., Bhgford, E. R., & Bhgerman, D. (2011). Gaucher disease glucocerebrosidase and alpha-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell, 146(1), 37-52. https://doi.org/10.1016/j.cell.2011.06.001

Nalls, M. A., Blauwendraat, C., Vallerga, C. L., Heilbron, K., Bandres-Ciga, S., Chang, D., Tan, M., Kia, D. A., Noyce, A. J., Xue, A., Bras, J., Young, E., von Coelln, R., Simon-Sanchez, J., Schulte, C., Sharma, M., Krohn, L., Pihlstrom, L., Siitonen, A., ... Singleton, A. B. (2019). Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: A meta-analysis of genome-wide association studies. Lancet Neurology, 18(12), 1091-1102. https://doi.org/10.1016/S1474-4422(19)30320-5

Parkinson's Foundation. (2024). Statistics. https://www.parkinson.org/understanding-parkinsons/statistics

Satake, W., Nakabayashi, Y., Mizuta, I., Hirota, Y., Ito, C., Kubo, M., Kawaguchi, T., Tsunoda, T., Watanabe, M., Takeda, A., Tomiyama, H., Nakashima, K., Hasegawa, K., Obata, F., Yoshikawa, T., Kawakami, H., Sakoda, S., Yamamoto, M., Hattori, N., ... Toda, T. (2009). Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. Nature Genetics, 41(12), 1303-1307. https://doi.org/10.1038/ng.485

Schneider, S. A., & Bhatt, M. H. (2020). Current concepts in the treatment of LRRK2 and GBA-associated Parkinson's disease. Current Neurology and Neuroscience Reports, 20(8), 1-10. https://doi.org/10.1007/s11910-020-01062-w

Sidransky, E., Nalls, M. A., Aasly, J. O., Aharon-Peretz, J., Annesi, G., Barbosa, E. R., Bar-Shira, A., Berg, D., Bras, J., Brice, A., Chen, C. M., Clark, L. N., Condroyer, C., De Marco, E. V., Durr, A., Eblan, M. J., Fahn, S., Farrer, M. J., Fung, H. C., ... Ziegler, S. G. (2009). Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. New England Journal of Medicine, 361(17), 1651-1661. https://doi.org/10.1056/NEJMoa0901281

Simon-Sanchez, J., Schulte, C., Bras, J. M., Sharma, M., Gibbs, J. R., Berg, D., Paisan-Ruiz, C., Lichtner, P., Scholz, S. W., Hernandez, D. G., Kruger, R., Federoff, M., Klein, C., Goate, A., Perlmutter, J., Bonin, M., Nalls, M. A., Illig, T., Gieger, C., ... Gasser, T. (2009). Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nature Genetics, 41(12), 1308-1312. https://doi.org/10.1038/ng.487

Soldner, F., Stelzer, Y., Shivalila, C. S., Abraham, B. J., Latourelle, J. C., Barrasa, M. I., Goldmann, J., Myers, R. H., Young, R. A., & Jaenisch, R. (2016). Parkinson-associated risk variant in distal enhancer of alpha-synuclein modulates target gene expression. Nature, 533(7601), 95-99. https://doi.org/10.1038/nature17939

Spillantini, M. G., Schmidt, M. L., Lee, V. M., Trojanowski, J. Q., Jakes, R., & Goedert, M. (1997). Alpha-synuclein in Lewy bodies. Nature, 388(6645), 839-840. https://doi.org/10.1038/42166

Tanner, C. M., Ottman, R., Goldman, S. M., Ellenberg, J., Chan, P., Mayeux, R., & Langston, J. W. (1999). Parkinson disease in twins: An etiologic study. JAMA, 281(4), 341-346. https://doi.org/10.1001/jama.281.4.341

West, A. B., Moore, D. J., Biskup, S., Bugber, A., Smith, W. W., Ross, C. A., Bhse, V. L., & Bhwson, T. M. (2005). Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proceedings of the National Academy of Sciences, 102(46), 16842-16847. https://doi.org/10.1073/pnas.0507360102

---

Related Reading

• APOE4 and Alzheimer's risk
• polygenic risk scores
• benefits of genetic testing
• DNA mutation rates and health risks